DGIdb - DAUNORUBICIN Drug Record

DAUNORUBICIN chembl:CHEMBL178 ApprovedAntineoplasticImmunotherapy

Alternate Names:

FI-6339
NSC-83142
DAUNORUBICIN
RP-13057
RP 13057
DAUNOXOME
CERUBIDINE
VALRUBICIN IMPURITY, DAUNORUBICIN
FI 6339
LEUKAEMOMYCIN C
(8S-CIS)-8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-ALPHA-L-LYXO-HEXOPYRANNOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPTHACENEDIONE
RUBIDOMYCIN
NDC-0082-4155
ACETYLADRIAMYCIN
(+)-DAUNOMYCIN
DAUNOMYCIN
CERUBIDINE®
DAUNORUBICINA
DAUNORUBICINUM
DAUNORUBICINE
drugbank:00694
pubchem.compound:30323
rxcui:3109
chemidplus:20830-81-3
chembl:CHEMBL178

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(7 More Sources)

Publications:

Guerrant W et al., 2012, Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors., J Med Chem
López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
Caldwell et al., 2013, Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia., PLoS ONE
Aubel-Sadron et al., 1984, Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review., Biochimie
Zunino et al., 1990, DNA topoisomerase II as the primary target of anti-tumor anthracyclines., Anticancer Drug Des.
McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.
Bains OS et al., 2010, Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin., J Pharmacol Exp Ther
Thompson P et al., 2014, Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group., Cancer Chemother Pharmacol
Drenberg CD et al., 2016, Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia., Clin Pharmacol Ther
Schröterová et al., 2004, The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro., Physiol Res
FitzGerald et al., 1987, Inhibition of thymidylate synthase in intact L1210 cells by ara-C, daunomycin, hydroxyurea and 3,4-dihydroxybenzylamine., Anticancer Drug Des.
Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
He H et al., 2014, Association of nitric oxide synthase 3 (NOS3) 894 G>T polymorphism with prognostic outcomes of anthracycline in Chinese patients with acute myeloid leukaemia., Clin Exp Pharmacol Physiol
Bains OS et al., 2010, Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism., J Pharmacol Exp Ther
Bagrintseva et al., 2005, FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)., Blood
Stone et al., 2017, Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation., N. Engl. J. Med.
Fiedler et al., 2015, A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations., Br. J. Haematol.
Stone et al., 2012, Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia., Leukemia
Shi W et al., 2011, Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans., Bioorg Med Chem
Bains OS et al., 2009, Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin., Drug Metab Dispos
Xu et al., 2005, p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer., Clin. Cancer Res.
Gutierrez-Camino A et al., 2017, PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort., Clin Pharmacol Ther
Elgie et al., 1999, Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML., Adv. Exp. Med. Biol.
He H et al., 2015, Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia., Eur J Clin Pharmacol
Megías-Vericat JE et al., 2015, Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies., Pharmacogenomics J
Gréen H et al., 2012, Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype., Pharmacogenomics J
Kim DH et al., 2006, Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia., Int J Cancer
Durdux et al., Fluorescence-based assessment of LRP activity: a comparative study., Anticancer Res.
Wesselborg et al., 1999, Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction., Blood
Huang RS et al., 2008, Genetic variants contributing to daunorubicin-induced cytotoxicity., Cancer Res
Stacy AE et al., 2013, Molecular pharmacology of ABCG2 and its role in chemoresistance., Mol Pharmacol
Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
Bour-Dill et al., 2000, Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis., Cytometry
Virappane et al., 2008, Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party., J. Clin. Oncol.
Howlett et al., 1999, Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation., Biochem. J.
Amitai Y et al., 1996, Glucose-6-phosphate dehydrogenase deficiency severely restricts the biotransformation of daunorubicin in human erythrocytes., J Lab Clin Med
Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol

DAUNORUBICIN NRP2

Interaction Score: 1.9

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18451141

Sources:
PharmGKB
DAUNORUBICIN AKR7A2

Interaction Score: 0.95

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20837989

Sources:
PharmGKB
DAUNORUBICIN SETD4

Interaction Score: 0.95

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19204081

Sources:
PharmGKB
DAUNORUBICIN AKR1C4

Interaction Score: 0.95

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20837989

Sources:
PharmGKB
DAUNORUBICIN GATA1

Interaction Score: 0.95

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type megakaryocytic leukemia

Response Type decreased response

Approval Status Preclinical - Cell culture

PMIDs:
23874683

Sources:
JAX-CKB
DAUNORUBICIN RPSA

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15161018

Sources:
NCI
DAUNORUBICIN ATP7B

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25119182

Sources:
PharmGKB
DAUNORUBICIN CBR3

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20007405

Sources:
PharmGKB
DAUNORUBICIN IKZF1

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30044693

Sources:
CIViC
DAUNORUBICIN CBR1

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19204081

Sources:
PharmGKB
DAUNORUBICIN PNPLA3

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28744905

Sources:
PharmGKB
DAUNORUBICIN WT1

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18591546

Sources:
CIViC
DAUNORUBICIN DROSHA

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24614921

Sources:
PharmGKB
DAUNORUBICIN FMO3

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25119182

Sources:
PharmGKB
DAUNORUBICIN BMP7

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
DAUNORUBICIN LINC00251

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
DAUNORUBICIN AKR1C3

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20837989

Sources:
PharmGKB
DAUNORUBICIN DNMT3A

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration DNMT3A:.

PMIDs:
None found

Sources:
CGI
DAUNORUBICIN DOK5

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
DAUNORUBICIN DCK

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25119182

Sources:
PharmGKB
DAUNORUBICIN SLC28A3

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DAUNORUBICIN GATA3

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24141364

Sources:
PharmGKB
DAUNORUBICIN FAS

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10216102

Sources:
NCI
DAUNORUBICIN CYP1A1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15588138

Sources:
NCI
DAUNORUBICIN TOP2A

Interaction Score: 0.08

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name CPX-351, cytarabine + daunorubicin

PMIDs:
6380596 1963303 9494516 22260166

Sources:
DTC TdgClinicalTrial NCI
DAUNORUBICIN NOS3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24684492

Sources:
PharmGKB
DAUNORUBICIN TYMS

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2967076

Sources:
NCI PharmGKB
DAUNORUBICIN TYMSOS

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DAUNORUBICIN UGT1A6

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DAUNORUBICIN FLT3

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cytarabine + Daunorubicin + Midostaurin

Indication/Tumor Type acute myeloid leukemia

Response Type sensitive

PMIDs:
15626738 28644114 25818407 22627678

Sources:
JAX-CKB NCI CIViC
DAUNORUBICIN TOP2B

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name CPX-351, cytarabine + daunorubicin

Novel drug target Established target

PMIDs:
6380596 1963303

Sources:
TdgClinicalTrial
DAUNORUBICIN NPM1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration NPM1:.

PMIDs:
None found

Sources:
CGI
DAUNORUBICIN APP

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10510309

Sources:
NCI
DAUNORUBICIN HDAC11

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
DAUNORUBICIN RARG

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DAUNORUBICIN HDAC9

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
DAUNORUBICIN HDAC10

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
DAUNORUBICIN HDAC7

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
DAUNORUBICIN HDAC5

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
DAUNORUBICIN HDAC4

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
DAUNORUBICIN HDAC8

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
DAUNORUBICIN HDAC3

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
DAUNORUBICIN HDAC2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
DAUNORUBICIN HDAC6

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
DAUNORUBICIN GSTP1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25119182

Sources:
PharmGKB
DAUNORUBICIN ABCC1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10655559

Sources:
NCI
DAUNORUBICIN HDAC1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22260166

Sources:
DTC
DAUNORUBICIN SLCO1B1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26663398

Sources:
PharmGKB
DAUNORUBICIN ABCG2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24021215

Sources:
PharmGKB
DAUNORUBICIN CBFB

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN ABCB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10500777 25567217 25558979 20938465 16331627

Sources:
NCI PharmGKB
DAUNORUBICIN RUNX1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN G6PD

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8648264

Sources:
PharmGKB
DAUNORUBICIN TOP1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21094049

Sources:
DTC
DAUNORUBICIN KMT2A

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration MLL__.

PMIDs:
None found

Sources:
CGI
DAUNORUBICIN THRB

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN BLM

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN RECQL

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN APEX1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN TP53

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

Approval Status Phase I

PMIDs:
16243804

Sources:
JAX-CKB
DAUNORUBICIN HTT

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN USP1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN POLK

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN KDM4E

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN MAPT

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DAUNORUBICIN EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TdgClinicalTrial: DAUNORUBICIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: DAUNORUBICIN

Version: 14-September-2017

Alternate Names:

C1583 NCI drug code

Drug Info:

Publications:

Schröterová et al., 2004, The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro., Physiol Res

Elgie et al., 1999, Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML., Adv. Exp. Med. Biol.

Bour-Dill et al., 2000, Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis., Cytometry

NCI: DAUNOMYCIN

Version: 14-September-2017

Alternate Names:

C1583 NCI drug code

Drug Info:

Publications:

FitzGerald et al., 1987, Inhibition of thymidylate synthase in intact L1210 cells by ara-C, daunomycin, hydroxyurea and 3,4-dihydroxybenzylamine., Anticancer Drug Des.

Howlett et al., 1999, Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation., Biochem. J.

DTC: DAUNORUBICIN

Version: 02-September-2020

Alternate Names:

CHEMBL178 ChEMBL Drug ID

Drug Info:

Publications:

Guerrant W et al., 2012, Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors., J Med Chem

Shi W et al., 2011, Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans., Bioorg Med Chem

JAX-CKB: Daunorubicin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Xu et al., 2005, p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer., Clin. Cancer Res.

Stone et al., 2012, Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia., Leukemia

Fiedler et al., 2015, A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations., Br. J. Haematol.

JAX-CKB: Daunoxome
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Xu et al., 2005, p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer., Clin. Cancer Res.

PharmGKB: daunorubicin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One

Drenberg CD et al., 2016, Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia., Clin Pharmacol Ther

Huang RS et al., 2008, Genetic variants contributing to daunorubicin-induced cytotoxicity., Cancer Res

CIViC: DAUNORUBICIN

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Bagrintseva et al., 2005, FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)., Blood

Virappane et al., 2008, Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party., J. Clin. Oncol.

Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol

TTD: Daunorubicin
- Version: 2020.06.01
Alternate Names:

D01XWG TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL178
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
CGI: Daunorubicin
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Indication/Tumor Type	megakaryocytic leukemia
Response Type	decreased response
Approval Status	Preclinical - Cell culture

Novel drug target	Established target
Trial Name	CPX-351, cytarabine + daunorubicin

combination therapy	Cytarabine + Daunorubicin + Midostaurin
Indication/Tumor Type	acute myeloid leukemia
Response Type	sensitive

Indication/Tumor Type	breast cancer
Response Type	predicted – sensitive
Approval Status	Phase I

Drug family	Chemotherapy
Alteration	DNMT3A:.

DAUNORUBICIN Drug Record

DAUNORUBICIN chembl:CHEMBL178 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18451141

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20837989

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19204081

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20837989

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type megakaryocytic leukemia Response Type decreased response Approval Status Preclinical - Cell culture

PMIDs: 23874683

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15161018

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25119182

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20007405

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 30044693

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19204081

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28744905

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18591546

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24614921

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25119182

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26590194

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26590194

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20837989

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Drug family Chemotherapy Alteration DNMT3A:.

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26590194

Interaction Types & Directionality:

n/a

PMIDs:
18451141

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20837989

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19204081

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20837989

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type megakaryocytic leukemia

Response Type decreased response

Approval Status Preclinical - Cell culture

PMIDs:
23874683

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
15161018

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25119182

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20007405

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30044693

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
19204081

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28744905

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18591546

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
24614921

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25119182

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26590194

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26590194

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20837989

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy

Alteration DNMT3A:.

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

n/a

PMIDs:
26590194

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25119182

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24141364

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10216102

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15588138

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name CPX-351, cytarabine + daunorubicin

PMIDs:
6380596 1963303 9494516 22260166

Sources:
DTC TdgClinicalTrial NCI

Interaction Types & Directionality:

n/a

PMIDs:
24684492